Pritor

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Telmisartan

Available from:

Bayer AG

ATC code:

C09CA07

INN (International Name):

telmisartan

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

HypertensionTreatment ta'l-ipertensjoni essenzjali fl-adulti. Kardjovaskulari preventionReduction tal-morbidità kardjovaskulari f'pazjenti bi: - manifest aterotrombotiċi mard kardjovaskulari (passat ta ' mard koronarju tal-qalb, puplesija, jew mard arterjali periferali) jew;dijabete tat-tip 2 mellitus dokumentata-mira-ħsara fl-organi.

Product summary:

Revision: 29

Authorization status:

Awtorizzat

Authorization date:

1998-12-11

Patient Information leaflet

                                36
B. FULJETT TA’ TAGĦRIF
37
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
PRITOR 20 MG PILLOLI
telmisartan
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Pritor u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Pritor
3.
Kif għandek tieħu Pritor
4.
Effetti sekondarji possibbli
5.
Kif taħżen Pritor
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU PRITOR U GЋALXIEX JINTUŻA
Pritor jagħmel parti minn klassi ta’ mediċini magħrufa bħala
antagonisti tar-riċetturi ta’ angiotensin II.
Angiotensin II hu sustanza magħmula fil-ġisem tiegħek li tikkawża
djieq fil-vini/arterji tad-demm
jidjiequ, u b’hekk tiżdied il-pressjoni tad-demm. Pritor jimblokka
l-effett ta’ angiotensin II biex
b’hekk il-vini u l-arterji jitwessgħu, u l-pressjoni tad-demm
tiegħek tonqos.
PRITOR JINTUŻA biex jikkura pressjoni għolja essenzjali (pressjoni
tad-demm għolja) f’pazjenti adulti.
‘Essenzjali’ tfisser li pressjoni tad-demm għolja mhijiex
ikkawżata minn xi kundizzjoni oħra.
Jekk il-pressjoni tad-demm għolja ma tkunx ikkurata, tista’
tagħmel ħsara lill-vini jew lill-arterji
f’diversi organi, u dan xi kultant jista’ jwassal għal attakk
tal-qalb, insuffiċjenza tal-kliewi jew tal-
qalb, puplesija, jew għama. Ġeneralment ma jkunx hemm sintomi ta’
pressjoni tad-demm għolja qabel
ma ssir il-ħsara. Għaldaqstant hu importanti li tkejjel il-pressjoni
tad-demm regolarmen
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Pritor 20 mg pilloli
Pritor 40 mg pilloli
Pritor 80 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Pritor 20 mg pilloli
Kull pillola fiha 20 mg telmisartan.
Pritor 40 mg pilloli
Kull pillola fiha 40 mg telmisartan.
Pritor 80 mg pilloli
Kull pillola fiha 80 mg telmisartan.
Eċċipjenti b’effett magħruf
Kull pillola ta’ 20 mg fiha 84 mg ta’ sorbitol (E420).
Kull pillola ta’ 40 mg fiha 169 mg ta’ sorbitol (E420).
Kull pillola ta’ 80 mg fiha 338 mg ta’ sorbitol (E420).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola
Pritor 20 mg pilloli
Pilloli bojod tondi ta’ 2.5 mm li fuqhom hemm imnaqqax in-numru
tal-kodiċi ‘50H’ fuq naħa waħda u
l-logo tal-kumpanija fuq in-naħa l-oħra.
Pritor 40 mg pilloli
Pilloli bojod ta’ 3.8 mm b’forma oblunga li fuqhom hemm imnaqqax
in-numru tal-kodiċi ‘51H’ fuq
naħa waħda.
Pritor 80 mg pilloli
Pilloli bojod ta’ 4.6 mm b’forma oblunga li fuqhom hemm imnaqqax
in-numru tal-kodiċi ‘52H’ fuq
naħa waħda.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Pressjoni għolja
Il-kura ta’ pressjoni tad-demm għolja essenzjali fl-adulti.
Prevenzjoni kardjovaskulari
Tnaqqis ta’ morbożità kardjovaskulari f’adulti bi:

mard kardjovaskulari aterotrombotiku sintomatiku (storja medika ta’
mard koronarju tal-qalb,
puplesija, jew mard arterjali periferali) jew
3

dijabete mellitus ta’ tip 2 bi ħsara dokumentata tal-organu
fil-mira
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
_Kura ta’ pressjoni tad-demm għolja essenzjali_
Id-doża effettiva normalment hi ta’ 40 mg darba kuljum. Xi pazjenti
jistgħu jibbenefikaw anke b’doża
ta’ 20 mg kuljum. F’każijiet fejn il-pressjoni ta’ demm
fil-mira ma tintlaħaqx, id-doża ta’ telmisartan
tista’ tiżdied għal massimu ta’ 80 mg darba kuljum. Inkella,
telmisartan jista’ jintuża flimkien ma’ tipi
ta’ dijuretiċi tat-tip thiazid
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-12-2020
Public Assessment Report Public Assessment Report Bulgarian 05-11-2015
Patient Information leaflet Patient Information leaflet Spanish 10-12-2020
Public Assessment Report Public Assessment Report Spanish 05-11-2015
Patient Information leaflet Patient Information leaflet Czech 10-12-2020
Public Assessment Report Public Assessment Report Czech 05-11-2015
Patient Information leaflet Patient Information leaflet Danish 10-12-2020
Public Assessment Report Public Assessment Report Danish 05-11-2015
Patient Information leaflet Patient Information leaflet German 10-12-2020
Public Assessment Report Public Assessment Report German 05-11-2015
Patient Information leaflet Patient Information leaflet Estonian 10-12-2020
Public Assessment Report Public Assessment Report Estonian 05-11-2015
Patient Information leaflet Patient Information leaflet Greek 10-12-2020
Public Assessment Report Public Assessment Report Greek 05-11-2015
Patient Information leaflet Patient Information leaflet English 10-12-2020
Public Assessment Report Public Assessment Report English 05-11-2015
Patient Information leaflet Patient Information leaflet French 10-12-2020
Public Assessment Report Public Assessment Report French 05-11-2015
Patient Information leaflet Patient Information leaflet Italian 10-12-2020
Public Assessment Report Public Assessment Report Italian 05-11-2015
Patient Information leaflet Patient Information leaflet Latvian 10-12-2020
Public Assessment Report Public Assessment Report Latvian 05-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-12-2020
Public Assessment Report Public Assessment Report Lithuanian 05-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 10-12-2020
Public Assessment Report Public Assessment Report Hungarian 05-11-2015
Patient Information leaflet Patient Information leaflet Dutch 10-12-2020
Public Assessment Report Public Assessment Report Dutch 05-11-2015
Patient Information leaflet Patient Information leaflet Polish 10-12-2020
Public Assessment Report Public Assessment Report Polish 05-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 10-12-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 10-12-2020
Public Assessment Report Public Assessment Report Portuguese 05-11-2015
Patient Information leaflet Patient Information leaflet Romanian 10-12-2020
Public Assessment Report Public Assessment Report Romanian 05-11-2015
Patient Information leaflet Patient Information leaflet Slovak 10-12-2020
Public Assessment Report Public Assessment Report Slovak 05-11-2015
Patient Information leaflet Patient Information leaflet Slovenian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 10-12-2020
Public Assessment Report Public Assessment Report Slovenian 05-11-2015
Patient Information leaflet Patient Information leaflet Finnish 10-12-2020
Public Assessment Report Public Assessment Report Finnish 05-11-2015
Patient Information leaflet Patient Information leaflet Swedish 10-12-2020
Public Assessment Report Public Assessment Report Swedish 05-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 10-12-2020
Patient Information leaflet Patient Information leaflet Icelandic 10-12-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 10-12-2020
Patient Information leaflet Patient Information leaflet Croatian 10-12-2020
Public Assessment Report Public Assessment Report Croatian 05-11-2015

Search alerts related to this product

View documents history